Dicerna's funding engine

Second generation RNAi company Dicerna Pharmaceuticals Inc. secured a $25 million series B round last week led by new investor Domain Associates, with participation from existing investors Oxford Bioscience Partners, Skyline Ventures and Abingworth.

"In the current financing environment, the presence of a true platform technology which can be licensed out on a very narrow, target-specific basis provides another way to raise capital," said Domain's Brian Halak, who joined the board...